Viridian Therapeutics

Yahoo Finance • 10 days ago

Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)

* Viridian Therapeutics (NASDAQ:VRDN [https://seekingalpha.com/symbol/VRDN]) announced that its compensation committee has approved the grant of non-qualified stock options to purchase 147,650 shares of its common stock to four new emplo... Full story

Yahoo Finance • 2 months ago

Viridian licenses thyroid eye disease treatments to Kissei in Japan

WALTHAM, Mass. - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a clinical-stage biotechnology company with a market capitalization of $1.37 billion, has entered into an exclusive licensing agreement with Kissei Pharmaceutical Co., Ltd. for th... Full story

Yahoo Finance • 4 months ago

Viridian Therapeutics' SWOT analysis: promising TED treatment stock faces pivotal year

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a $1.29 billion market cap biopharmaceutical company focused on developing treatments for thyroid eye disease (TED), stands at a critical juncture in its journey to bring innovative therapies to m... Full story

Yahoo Finance • 2 years ago

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • 2 years ago

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds mu... Full story

Yahoo Finance • 2 years ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious an... Full story

Yahoo Finance • 2 years ago

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announc... Full story

Yahoo Finance • 2 years ago

UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial of VRDN-001 - - Poster presentations to... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today annou... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today annou... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story

Yahoo Finance • 3 years ago

Viridian Appoints Scott Myers as President and Chief Executive Officer

WALTHAM, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious a... Full story

Yahoo Finance • 3 years ago

Zenas BioPharma 的合作夥伴 Viridian Therapeutics 宣佈正在進行的評估低劑量 VRDN-001 (ZB001) 治療甲狀腺眼病 (TED) 患者的 1/2 期試驗獲得積極數據

兩次輸注 3 mg/kg 後，TED 的體徵和症狀均有顯著且迅速的改善，與之前 10 和 20 mg/kg 的結果基本一致在 3 mg/kg VRDN-001 治療的患者中，67% 獲得眼球突出反應，56% 獲得總體反應，67% 達到臨床活動評分 (CAS) 為 0 或 1，20% 的複視完全消退迄今為止，在接受 VRDN-001 治療的所有 21 名患者中，71% 獲得眼球突出反應，67% 獲得總體反應，62% 達到CAS 為 0 或 1，54% 的複視完全消退，所有劑量... Full story

Yahoo Finance • 3 years ago

ゼナス･バイオファーマ (Zenas BioPharma) のパートナーであるヴィリジアン･セラピューティクス (Viridian Therapeutics)、甲状腺眼症 (TED) 患者を対象とした低用量VRDN-001 (ZB001) を評価する進行中の第1/2相試験で良好なデータが得られたことを発表

3 mg/kgを2回静注投与した後、TEDの徴候および症状の両方が有意かつ迅速に改善し、10 mg/kgおよび20 mg/kgの先行成績と概ね一致3 mg/kgのVRDN-001を投与された患者のうち、67%が眼球突出に奏功、56%に全体的な奏功、67%が臨床活動スコア (CAS) 0または1を達成し、20%で複視が完全に消失これまでにVRDN-001を投与された21名の患者のうち、71%が眼球突出に奏功、67%に全体的な奏功、62%が臨床活動スコア (CAS) 0または1... Full story

Yahoo Finance • 3 years ago

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56%... Full story

Yahoo Finance • 3 years ago

Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story